ABC Talking Points on Convalescent Plasma

(April 3, 2020)

The entire blood community is working closely with the U.S. Food and Drug Administration (FDA) to begin collecting and distributing convalescent plasma from individuals who have recovered from COVID-19.

While COVID-19 currently has no proven treatment, it is possible that convalescent plasma that contains antibodies to SARS-CoV-2 (the virus that causes COVID-19) may provide passive immunity to certain patients with severe forms of COVID-19.

Individuals may be eligible to donate convalescent plasma if they meet all regular blood donor requirements and meet the following minimum requirements:

- prior diagnosis for COVID-19 by laboratory test and complete resolution of symptoms for at least 28 days or;
- prior diagnosis for COVID-19 by laboratory test and complete resolution of symptoms for at least 14 days with a follow-up negative COVID-19 test or;
- prior diagnosis for COVID-19 by clinical symptoms/evaluation and complete resolution of symptoms for at least 28 days; or
- prior diagnosis for COVID-19 by clinical symptoms/evaluation and complete resolution of symptoms for at least 14 days with a follow-up negative COVID-19 test.

If the individual meets the criteria above, the donor center will further evaluate their eligibility which will include routine donor screening as well as possible additional pre-screen and testing related to COVID.

Individuals who have had a confirmed case of COVID-19 and have since experienced a full recovery should contact their local blood center to determine their eligibility. To find the blood center closest to you, visit https://americasblood.org/for-donors/find-a-blood-center/.

Physicians and hospitals can learn more by visiting the FDA website on convalescent plasma emergency use at: https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds.